Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 2, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 3, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001104659-26-039697
Filed / recorded
Apr 3, 2026, 10:22 PM UTC
Added to OQRO
Oct 8, 2026, 1:28 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
AEON Biopharma, Inc.
Issuer CIK
1837607
Ticker
AEON
Reporting person
John Bencich
Relationship
Officer
Officer title
CHIEF FINANCIAL OFFICER
Security
Class A Common Stock
Table
Non-derivative (Table I)
Transaction date
Apr 2, 2026
Transaction code
A
Shares / units
754,717
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
754,717
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents an award of restricted stock units granted on April 1, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.